Featured Research

from universities, journals, and other organizations

Promising cervical cancer study: Combining drugs, chemo to extend life

Date:
February 21, 2014
Source:
St. Joseph's Hospital and Medical Center
Summary:
New research has revealed that women with advanced cervical cancer live about four months longer with the combined use of bevacizumab (Avastin®) and chemotherapy compared to chemotherapy alone. Women who combined bevacizumab with chemotherapy lived an average of 17 months after diagnosis, while those who received chemotherapy alone lived 13.3 months. The multi-site research project is expected to change the standard of care in advanced cervical cancer.

Research on cervical cancer performed by a physician at the University of Arizona Cancer Center at St. Joseph's Hospital and Medical Center has been published in the New England Journal of Medicine. The multi-site research project by Bradley J. Monk, MD, is expected to change the standard of care for women with advanced cervical cancer.

The featured research revealed that women with advanced cervical cancer live about four months longer with the combined use of bevacizumab (Avastin®) and chemotherapy compared to chemotherapy alone. Women who combined bevacizumab with chemotherapy lived an average of 17 months after diagnosis, while those who received chemotherapy alone lived 13.3 months.

"This research proves that there are new options for patients with metastatic cervical cancer," says Dr. Monk, the project's senior author. "I predict that adding bevacizumab to chemotherapy will become the new standard of care." Dr. Monk is nationally recognized for his expertise in cervical cancer and chairs the Gynecologic Oncology Cervical Cancer Committee for the National Cancer Institute funded Gynecologic Oncology Group. Krishnansu S. Tewari, MD, at the University of California Irvine was the first author on the study published online February 20 in the Journal.

The research was conducted between April 2009 and January 2012. A total of 452 women participated in the trial and were enrolled from 164 institutions in the United States and Spain. St. Joseph's Hospital and Medical Center was the only site enrolling in Arizona.

During the clinical trial, patients were randomly assigned to groups who only received chemotherapy and to groups who received both chemotherapy with bevacizumab.

Approximately 12,000 cases of cervical cancer are diagnosed in the United States annually, and with continued increases in vaccinations, numbers of cases are expected to decrease further. However, for vulnerable populations without access to health care, cervical cancers remains a serious problem, with 500,000 new cases and 250,000 deaths annually.

"There has been a large unmet medical need for active treatments for cervical cancer," says Dr. Monk. "We believe the results of this study are a significant step forward and now we will move to trying to add bevacizumab to a front-line treatment when cancers are more curable, rather than using it at the time of recurrence."


Story Source:

The above story is based on materials provided by St. Joseph's Hospital and Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Krishnansu S. Tewari, Michael W. Sill, Harry J. Long, Richard T. Penson, Helen Huang, Lois M. Ramondetta, Lisa M. Landrum, Ana Oaknin, Thomas J. Reid, Mario M. Leitao, Helen E. Michael, Bradley J. Monk. Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine, 2014; 370 (8): 734 DOI: 10.1056/NEJMoa1309748

Cite This Page:

St. Joseph's Hospital and Medical Center. "Promising cervical cancer study: Combining drugs, chemo to extend life." ScienceDaily. ScienceDaily, 21 February 2014. <www.sciencedaily.com/releases/2014/02/140221150453.htm>.
St. Joseph's Hospital and Medical Center. (2014, February 21). Promising cervical cancer study: Combining drugs, chemo to extend life. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2014/02/140221150453.htm
St. Joseph's Hospital and Medical Center. "Promising cervical cancer study: Combining drugs, chemo to extend life." ScienceDaily. www.sciencedaily.com/releases/2014/02/140221150453.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Artificial Sweetener Could Promote Diabetes

Artificial Sweetener Could Promote Diabetes

Newsy (Sep. 17, 2014) — Doctors once thought artificial sweeteners lacked the health risks of sugar, but a new study says they can impact blood sugar levels the same way. Video provided by Newsy
Powered by NewsLook.com
Ebola Vaccine Trial Gets Underway at Oxford University

Ebola Vaccine Trial Gets Underway at Oxford University

AFP (Sep. 17, 2014) — A healthy British volunteer is to become the first person to receive a new vaccine for the Ebola virus after US President Barack Obama called for action against the epidemic and warned it was "spiralling out of control." Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Obesity Rates Steady Even As Americans' Waistlines Expand

Obesity Rates Steady Even As Americans' Waistlines Expand

Newsy (Sep. 17, 2014) — Researchers are puzzled as to why obesity rates remain relatively stable as average waistlines continue to expand. Video provided by Newsy
Powered by NewsLook.com
President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) — President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins